Cardiac sympathetic denervation for conventional treatment refractory arrhythmias

Mauricio Velásquez1, Liliana Fernández2, Carl S Leib3

  • 1Thoracic Surgery, Biomedical Research in Thorax. Universidad ICESI, Cali, Colombia.

Insights

Video-assisted cardiac sympathetic denervation (CSD) offers a safe alternative for refractory ventricular arrhythmias. This minimally invasive procedure showed significant improvement in patients with structural heart disease and hereditary conditions.

Area of Science:

  • Cardiology
  • Thoracic Surgery

Background:

  • Cardiac sympathetic denervation (CSD) is an option for arrhythmias unresponsive to standard treatments.
  • It is particularly relevant for ventricular arrhythmias in structural heart disease and hereditary conditions like long QT syndrome.

Purpose of the Study:

  • To evaluate the institutional experience and outcomes of video-assisted CSD in patients with refractory arrhythmias.
  • To assess the efficacy and safety of CSD in managing difficult-to-treat cardiac arrhythmias.

Main Methods:

  • An observational retrospective study analyzing patient records.
  • Included patients with ventricular arrhythmias refractory to medical treatment, ablation, or ICD implantation who underwent video-assisted CSD.

Main Results:

  • Six patients were included, most with structural heart disease (median age 56 ± 16 years, 67% male).
  • The procedure was well-tolerated with no complications and showed significant overall improvement.
  • Follow-up at 24 months revealed rare, mild recurrences in two patients and one ventricular fibrillation episode managed by ICD.

Conclusions:

  • Video-assisted CSD is a viable treatment option for dangerous arrhythmias resistant to conventional therapies.
  • It is especially recommended for recurrent ventricular tachycardia when other treatments fail.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
373
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
427
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
305
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
354